Loading…

The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs

Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one S...

Full description

Saved in:
Bibliographic Details
Published in:Brain research 2010-11, Vol.1362, p.150-159
Main Authors: Alonso-Alconada, Daniel, Alvarez, Francisco J, Alvarez, Antonia, Mielgo, Victoria E, Goñi-de-Cerio, Felipe, Rey-Santano, Maria C, Caballero, Amale, Martinez-Orgado, Jose, Hilario, Enrique
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3
cites cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3
container_end_page 159
container_issue
container_start_page 150
container_title Brain research
container_volume 1362
creator Alonso-Alconada, Daniel
Alvarez, Francisco J
Alvarez, Antonia
Mielgo, Victoria E
Goñi-de-Cerio, Felipe
Rey-Santano, Maria C
Caballero, Amale
Martinez-Orgado, Jose
Hilario, Enrique
description Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.
doi_str_mv 10.1016/j.brainres.2010.09.050
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_856757740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000689931002055X</els_id><sourcerecordid>856757740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhFSpfEBeyTOw4di4IVPGnUgUHiuBmOfak65A_i50g9tZ34A15Ema1W5C49GTZ8_tmPvmbLDsrYF1AUb3o1k20YYyY1hzoEeo1SLiXrQqteF7xEu5nKwCocl3X4iR7lFJHVyFqeJidcNBSl1W9ym6uNsicHUfbhHEKnkV0uJ2nyOz1NIY0sy8XH5iUz3nBc05VvzhMbCZVGMMcbM8cRiQzPfN2sNfIbDtjZJvddvoZ3O-bXyG5DQ7BkaBb4o4O1uJMfG-HJj3OHrS2T_jkeJ5mn9--uTp_n19-fHdx_voyd6Uu55z7ygrXVlJAK3WjSq-gVFTzKEsvRONs3Th0QgqupdRKaF07zlXDa9W0Xpxmzw59t3H6vmCazUDGsO_tiNOSjJaVkkqVcCepKlGoklwRWR1IF6eUIrZmG8Ng484UYPYxmc7cxmT2MRmoDcVEwrPjiKUZ0P-V3eZCwNMjYJOzfRvt6EL6xwnyqQpF3KsDh_R1PwJGk1zA0aEPFORs_BTu9vLyvxaup2hp6jfcYeqmJY4UjClM4gbMp_1S7XeqAOAg5VfxB3l5ycU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>763174484</pqid></control><display><type>article</type><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><source>Elsevier</source><creator>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</creator><creatorcontrib>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</creatorcontrib><description>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2010.09.050</identifier><identifier>PMID: 20858469</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Apoptosis ; Benzoxazines - pharmacology ; Benzoxazines - therapeutic use ; Biological and medical sciences ; Brain damage ; Calcium Channel Blockers - pharmacology ; Calcium Channel Blockers - therapeutic use ; Cannabinoid ; Cannabinoid Receptor Modulators - pharmacology ; Cannabinoid Receptor Modulators - therapeutic use ; Disease Models, Animal ; Female ; Fetus ; Hypoxia-Ischemia, Brain - drug therapy ; Hypoxia–ischemia ; Medical sciences ; Morpholines - pharmacology ; Morpholines - therapeutic use ; Naphthalenes - pharmacology ; Naphthalenes - therapeutic use ; Neurology ; Neuropharmacology ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Complications - drug therapy ; Psychodysleptics: hallucinogen ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Sheep, Domestic ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Brain research, 2010-11, Vol.1362, p.150-159</ispartof><rights>Elsevier B.V.</rights><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</citedby><cites>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23403717$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20858469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alonso-Alconada, Daniel</creatorcontrib><creatorcontrib>Alvarez, Francisco J</creatorcontrib><creatorcontrib>Alvarez, Antonia</creatorcontrib><creatorcontrib>Mielgo, Victoria E</creatorcontrib><creatorcontrib>Goñi-de-Cerio, Felipe</creatorcontrib><creatorcontrib>Rey-Santano, Maria C</creatorcontrib><creatorcontrib>Caballero, Amale</creatorcontrib><creatorcontrib>Martinez-Orgado, Jose</creatorcontrib><creatorcontrib>Hilario, Enrique</creatorcontrib><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Benzoxazines - pharmacology</subject><subject>Benzoxazines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain damage</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cannabinoid</subject><subject>Cannabinoid Receptor Modulators - pharmacology</subject><subject>Cannabinoid Receptor Modulators - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Fetus</subject><subject>Hypoxia-Ischemia, Brain - drug therapy</subject><subject>Hypoxia–ischemia</subject><subject>Medical sciences</subject><subject>Morpholines - pharmacology</subject><subject>Morpholines - therapeutic use</subject><subject>Naphthalenes - pharmacology</subject><subject>Naphthalenes - therapeutic use</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Psychodysleptics: hallucinogen</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Sheep, Domestic</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxiMEokvhFSpfEBeyTOw4di4IVPGnUgUHiuBmOfak65A_i50g9tZ34A15Ema1W5C49GTZ8_tmPvmbLDsrYF1AUb3o1k20YYyY1hzoEeo1SLiXrQqteF7xEu5nKwCocl3X4iR7lFJHVyFqeJidcNBSl1W9ym6uNsicHUfbhHEKnkV0uJ2nyOz1NIY0sy8XH5iUz3nBc05VvzhMbCZVGMMcbM8cRiQzPfN2sNfIbDtjZJvddvoZ3O-bXyG5DQ7BkaBb4o4O1uJMfG-HJj3OHrS2T_jkeJ5mn9--uTp_n19-fHdx_voyd6Uu55z7ygrXVlJAK3WjSq-gVFTzKEsvRONs3Th0QgqupdRKaF07zlXDa9W0Xpxmzw59t3H6vmCazUDGsO_tiNOSjJaVkkqVcCepKlGoklwRWR1IF6eUIrZmG8Ng484UYPYxmc7cxmT2MRmoDcVEwrPjiKUZ0P-V3eZCwNMjYJOzfRvt6EL6xwnyqQpF3KsDh_R1PwJGk1zA0aEPFORs_BTu9vLyvxaup2hp6jfcYeqmJY4UjClM4gbMp_1S7XeqAOAg5VfxB3l5ycU</recordid><startdate>20101129</startdate><enddate>20101129</enddate><creator>Alonso-Alconada, Daniel</creator><creator>Alvarez, Francisco J</creator><creator>Alvarez, Antonia</creator><creator>Mielgo, Victoria E</creator><creator>Goñi-de-Cerio, Felipe</creator><creator>Rey-Santano, Maria C</creator><creator>Caballero, Amale</creator><creator>Martinez-Orgado, Jose</creator><creator>Hilario, Enrique</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20101129</creationdate><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><author>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Benzoxazines - pharmacology</topic><topic>Benzoxazines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain damage</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cannabinoid</topic><topic>Cannabinoid Receptor Modulators - pharmacology</topic><topic>Cannabinoid Receptor Modulators - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Fetus</topic><topic>Hypoxia-Ischemia, Brain - drug therapy</topic><topic>Hypoxia–ischemia</topic><topic>Medical sciences</topic><topic>Morpholines - pharmacology</topic><topic>Morpholines - therapeutic use</topic><topic>Naphthalenes - pharmacology</topic><topic>Naphthalenes - therapeutic use</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Psychodysleptics: hallucinogen</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Sheep, Domestic</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alonso-Alconada, Daniel</creatorcontrib><creatorcontrib>Alvarez, Francisco J</creatorcontrib><creatorcontrib>Alvarez, Antonia</creatorcontrib><creatorcontrib>Mielgo, Victoria E</creatorcontrib><creatorcontrib>Goñi-de-Cerio, Felipe</creatorcontrib><creatorcontrib>Rey-Santano, Maria C</creatorcontrib><creatorcontrib>Caballero, Amale</creatorcontrib><creatorcontrib>Martinez-Orgado, Jose</creatorcontrib><creatorcontrib>Hilario, Enrique</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alonso-Alconada, Daniel</au><au>Alvarez, Francisco J</au><au>Alvarez, Antonia</au><au>Mielgo, Victoria E</au><au>Goñi-de-Cerio, Felipe</au><au>Rey-Santano, Maria C</au><au>Caballero, Amale</au><au>Martinez-Orgado, Jose</au><au>Hilario, Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2010-11-29</date><risdate>2010</risdate><volume>1362</volume><spage>150</spage><epage>159</epage><pages>150-159</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20858469</pmid><doi>10.1016/j.brainres.2010.09.050</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 2010-11, Vol.1362, p.150-159
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_856757740
source Elsevier
subjects Animals
Apoptosis
Benzoxazines - pharmacology
Benzoxazines - therapeutic use
Biological and medical sciences
Brain damage
Calcium Channel Blockers - pharmacology
Calcium Channel Blockers - therapeutic use
Cannabinoid
Cannabinoid Receptor Modulators - pharmacology
Cannabinoid Receptor Modulators - therapeutic use
Disease Models, Animal
Female
Fetus
Hypoxia-Ischemia, Brain - drug therapy
Hypoxia–ischemia
Medical sciences
Morpholines - pharmacology
Morpholines - therapeutic use
Naphthalenes - pharmacology
Naphthalenes - therapeutic use
Neurology
Neuropharmacology
Neuroprotective Agents - pharmacology
Neuroprotective Agents - therapeutic use
Pharmacology. Drug treatments
Pregnancy
Pregnancy Complications - drug therapy
Psychodysleptics: hallucinogen
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Sheep, Domestic
Vascular diseases and vascular malformations of the nervous system
title The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20cannabinoid%20receptor%20agonist%20WIN%2055,212-2%20reduces%20the%20initial%20cerebral%20damage%20after%20hypoxic%E2%80%93ischemic%20injury%20in%20fetal%20lambs&rft.jtitle=Brain%20research&rft.au=Alonso-Alconada,%20Daniel&rft.date=2010-11-29&rft.volume=1362&rft.spage=150&rft.epage=159&rft.pages=150-159&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/j.brainres.2010.09.050&rft_dat=%3Cproquest_cross%3E856757740%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=763174484&rft_id=info:pmid/20858469&rfr_iscdi=true